Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:
Breast Cancer
Prostate Cancer
Lung Cancer
Colorectal Cancer
Stomach Cancer
Ovarian Cancer
2005 Ankara University Faculty of Medicine
2011 Ankara University Faculty of Medicine Internal Medicine Specialist
2013 Dr. A. Y. Ankara Oncology EAH Medical Oncology Specialization
Specialization Thesis in Medicine: EFFECTS OF TELMISARTAN ON BONE CYCLE MARKERS
2006-2001 Ankara University Faculty of Medicine, Department of Internal Diseases (Internal Diseases Research Assistant)
2011-2012 Dr. Nafiz Körez Sincan State Hospital (Internal Medicine Specialist)
2012-2013 Polu District State Hospital (Internal Medicine Specialist – Chief Physician)
2013-2019 Abdurrahman Yurtaslan Ankara Oncology EAH Medical Oncology Clinic (Medical Oncology Minor Assistant)
2016-2021 Dr. Abdurrahman Yurtaslan Ankara Oncology EAH Medical Oncology Clinic (Medical Oncology Specialist)
Turkish Medical Oncology Association
Ankara Breast Diseases Association
A1. Eraslan, E., Yildiz, F., Ilhan, A., & Dogan, M. (2021). The Need for Effective Adjuvant Therapy in Uterine Leiomyosarcoma: A Single-centre Experience. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP, 31(8), 926-931. https://doi.org/10.29271/jcpsp.2021.08.926
A2. Eraslan, E., Doğan, M., Yildiz, F., İlhan, A., & Öksüzoğlu, Ö. B. (2021). Treatment options after regorafenib failure in metastatic colorectal cancer. European review for medical and pharmacological sciences, 25(9), 3470–3477. https://doi.org/10.26355/eurrev_202105_25828
A3. Eraslan, E., Adas, Y. G., Yildiz, F., Gulesen, A. I., Karacin, C., & Arslan, U. Y. (2021). Systemic Immune-inflammation Index (SII) Predicts Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP, 30(4), 399-404. doi: 10.29271/jcpsp.2021.04.399.
A4. Eraslan, E., & Arslan, U. Y. (2020). Long-term follow-up results of patients with sarcomatoid RCC: A retrospective evaluation of a single center experience. Journal of Surgery and Medicine, 4(9), 803-807. doi: 10.28982/josam.789516.
A5. Eraslan, E., & Doğan, M. (2021). Platelet-to-lymphocyte Ratio (PLR) as an Indicator of Survival in Rare Histopathological Subtypes of Renal Cell Carcinoma. Medical Science and Discovery, 8(4), 283-288. doi: 10.36472/msd.v8i4.535.
A6. Sütcüoğlu O, İlhan A, Tacar SY, Güven DC, Uçar G, Karadurmuş N, Yıldız F, Eraslan E, Uncu D, Tural D, Üner A, Günel N, Özdemir N, Kılıçkap S, Öksüzoğlu ÖB, Abstract A, Yazıcı O Thirty-day mortality rates after immunotherapy initiation. Immunotherapy. 2021 Oct 22. doi: 10.2217/imt-2021-0082. Epub ahead of print. PMID: 34676791.
A7. Helvaci, K., Eraslan, E., Yildiz, F., Tufan, G., Demirci, U., Berna Oksuzoglu, O., & Yalcintas Arslan, U. (2019). Comparison of clinicopathological and survival features of right and left colon cancers. J. BUON Off. J. Balk. Union Oncol, 24, 1845-1851.
A8. Yildiz, F., Eraslan, E., Ilhan, A., Demir, H., Demir, N., Erdur, E., ... & Demirci, U. (2020). Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. International Journal of Hematology & Oncology/UHOD: International Journal of Hematology & Oncology, 30(3). doi: 10.4999/uhod.
A9. Ozcelik, M., Seker, M., Eraslan, E., Koca, S., Yazilitas, D., Ercelep, O., ... & Aliustaoglu, M. (2016). Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology. Tumor Biology, 37(4), doi: 5231-5237. 10.1007/s13277-015-4359-1.
A10. Yildiz, F., Durnali, A., Eraslan, E., Ilhan, A., Tufan, G., Aslan, F., ... & Oksuzoglu, B. (2020). Outcomes of Autologous Stem Cell Transplantation (ASCT) in Relapsed/Refractory Germ Cell Tumors: Single Center Experience from Turkey. Urology Journal, 6004-6004. doi: 10.22037/uj.v16i7.6004.
A11. Yıldız, F., İlhan, A., Eraslan, E., Aslan, F., Tufan, G., Öksüzoğlu, B., & Demirci, U. (2020). Single Center Experiences with Pegfilgrastim as Secondary Prophylaxis. Turkish Journal of Oncology, 35(2), doi: 10.5505/tjo.2019.2087.
A12. Aslan, F., Demirci, U., Kızılgöz, D., Yıldız, F., Kabalak, P. A., Başal, F. B., Eraslan, E., Yılmaz, Ü., & Öksüzoğlu, B. (2020). Prognostic factors affecting survival in third-line treatment of advanced non-small cell lung cancer: Retrospective cohort study. Journal of Surgery and Medicine 2020;4(2):135-138. doi: 10.28982/josam.686819.
A13. Ekinci, A. Ş., Bal, Ö., Özatlı, T., Türker, İ., Eşbah, O., Demirci, A., Budakoğlu, B., Arslan, Ü. Y., Eraslan, E., & Öksüzoğlu, B. (2014). Gastric carcinoma with bone marrow metastasis: a case series. Journal of gastric cancer, 14(1), 54. doi: 10.5230/jgc.2014.14.1.54.
